{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:47:25Z","timestamp":1780944445439,"version":"3.54.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Enfortumab is a monoclonal antibody directed against nectin-4 and, when combined with vedotin, is an antibody\u2013drug conjugate approved for the treatment of locally advanced or metastatic urothelial cancers. A 75-year-old woman with stage IV papillary urothelial carcinoma of the bladder who completed cycle 2 of enfortumab vedotin (EV) infusions presented to our dermatology department for new-onset symmetric and painful dusky erythematous patches on the extremities and trunk without mucosal involvement. Two biopsies were obtained, which revealed an interface dermatitis with notable ring mitoses within the basal and suprabasal layers of the epidermis without epidermal necrosis. The patient was diagnosed with toxic erythema of chemotherapy and improved with application of triamcinolone 0.1% ointment twice daily without discontinuation of her EV infusions. Although a targeted therapy, EV commonly exhibits cutaneous side effects due to the expression of nectin-4 in the skin. Most cutaneous side effects are mild and can be managed symptomatically. However, severe drug-induced eruptions, such as toxic epidermal necrolysis, have been described. The histologic findings of EV associated skin eruptions can aid in correctly identifying the culprit drug and assist in management. This case provides insights for dermatologists by highlighting the common cutaneous side effects of EV and the associated histologic findings as this targeted therapy becomes increasingly utilized in the treatment of refractory neoplasms.<\/jats:p>","DOI":"10.1097\/dad.0000000000002750","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T14:03:36Z","timestamp":1717682616000},"page":"538-541","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Enfortumab Vedotin Drug Eruption: Cutaneous Adverse Events and Histopathologic Findings"],"prefix":"10.1097","volume":"46","author":[{"given":"Fiore","family":"Casale","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolyn","family":"Wanat","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Saab-Chalhoub","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical College of Wisconsin, Milwaukee, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2147\/OTT.S370900","article-title":"Targeted treatment of locally advanced and metastatic urothelial cancer: enfortumab vedotin in context","volume":"15","author":"Hoffman-Censits","year":"2022","journal-title":"Onco Targets Ther"},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","article-title":"Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma","volume":"85","author":"Hirotsu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"e1009","DOI":"10.1111\/jdv.18406","article-title":"Enfortumab vedotin-induced cutaneous adverse events manifesting as miliaria-like eruptions with the presence of keratinocyte apoptosis in clinically intact skin","volume":"36","author":"Oya","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"621591","DOI":"10.3389\/fonc.2021.621591","article-title":"Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens-Johnson Syndrome\/toxic epidermal necrolysis to dermal hypersensitivity reaction","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol"},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2022.02.019","article-title":"Life-threatening skin reaction with enfortumab vedotin: six cases","volume":"167","author":"Guerrois","year":"2022","journal-title":"Eur J Cancer"},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2013.08.008","article-title":"Increased frequencies of Th17 cells in drug eruptions","volume":"73","author":"Fujiyama","year":"2014","journal-title":"J Dermatol Sci"},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjd.21022","article-title":"Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin","volume":"187","author":"Penny","year":"2022","journal-title":"Br J Dermatol"},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjd.21230","article-title":"Response to \u2018Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin\u2019","volume":"187","author":"Oya","year":"2022","journal-title":"Br J Dermatol"},{"key":"R12-20250616","first-page":"e8102","article-title":"Flexural exanthema from enfortumab vedotin","volume":"12","author":"Keerty","year":"2020","journal-title":"Cureus"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:02:45Z","timestamp":1750096965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002750","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}